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Abstract: The transient receptor potential vanilloid 1 (TRPV1) is a thermoreceptor that responds 
to noxious temperatures, as well as to chemical agonists, such as vanilloids and protons. In 
addition, its channel activity is notably potentiated by proinflammatory mediators released upon 
tissue damage. The TRPV1 contribution to sensory neuron sensitization by proalgesic agents has 
signaled this receptor as a prime target for analgesic and anti-inflammatory drug intervention. 
However, TRPV1 antagonists have notably failed in clinical and preclinical studies because 
of their unwanted side effects. Recent reports have unveiled previously unrecognized anti-
inflammatory and protective functions of TRPV1 in several diseases. For instance, this channel 
has been suggested to play an anti-inflammatory role in sepsis. Therefore, the use of potent 
TRPV1 antagonists as a general strategy to treat inflammation must be cautiously considered, 
given the deleterious effects that may arise from inhibiting the population of channels that have a 
protective function. The use of TRPV1 antagonists may be limited to treating those pathologies 
where enhanced receptor activity contributes to the inflamed state. Alternatively, therapeutic 
paradigms, such as reduction of inflammatory-mediated increase of receptor expression in the 
cell surface, may be a better strategy to prevent abrogation of the TRPV1 subpopulation involved 
in anti-inflammatory and protective processes.
Keywords: transient receptor potential, nociceptor, capsaicin, pain, ion channel, analgesia
TRPV1 receptor
Transient receptor potential vanilloid 1 (TRPV1), also known as the capsaicin receptor, 
was first cloned from rat dorsal root ganglion neurons using an expression-cloning 
screening strategy.1 This newly cloned cDNA was first named VR1, for vanilloid 
receptor subtype 1. Because this receptor is a member of the transient receptor potential 
family of cation channels, it was given the name TRPV1 because it represented the first 
known member of the transient receptor potential vanilloid subfamily of transient recep-
tor potential channels. To date, TRPV1 orthologs have been identified in eukaryotes, 
including human, rat, guinea pig, rabbit, mouse, dog, and porcine tissues, but not in 
prokaryotes. The ability of TRPV1 to respond to noxious stimuli and to be functionally 
sensitized by proinflammatory mediators has signaled it as a “pathological” receptor, 
having a significant role in the pain transduction pathway, and in the maintenance of 
inflammatory conditions in a variety of diseases and injury states.
TRPV1 structure and expression
TRPV1 is an 838-amino acid protein with a molecular weight of 95 kDa, consisting 
of six transmembrane segments, with an amphipathic pore-forming region between Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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the fifth and sixth transmembrane segments, a large 
N-terminus   intracellular domain, and a C-terminal cytoso-
lic region   (Figure 1).   Functional TRPV1 channels exist as 
homomultimers,2 although functional heteroligomers may be 
formed between TRPV1 and TRPV33 or between TRPV1 and 
TRPV2,4,5 which may be responsible, at least in part, for the 
variable responses to agonists and antagonists. The 432-amino 
acid N-terminus contains at least six ankyrin repeats,6,7 which 
are essential for channel function8,9 and for orchestrating a 
plethora of protein–protein interactions that govern the assem-
bly of TRPV1-containing signalplexes.10,11 The 145-amino acid 
C-terminal contains subdomains involved in distinct channel 
functions. For instance, adjacent to the channel gate,12 a highly 
conserved region known as the transient receptor potential 
domain, is involved in the functional coupling of stimuli sens-
ing and gate opening.13,14 Furthermore, the C-terminus contains 
the molecular determinants for subunit tetramerization,15,16 two 
nucleotide-binding Walker-type sites,17 as well as consensus 
sequences for modulation by phosphoinositides and protein 
kinases.18,19 More notably, this region has been suggested to 
hold the temperature sensor of the receptor.20
TRPV1 shows a wide tissue distribution. High levels of 
expression are observed in dorsal root ganglia, trigeminal 
ganglia, and nodose ganglia.1 TRPV1 is predominantly 
expressed in small and medium diameter neurons, mainly in 
the peptidergic ones, that are important in the development of 
neurogenic pain and inflammation,21 and to a lesser extent in 
the nonpeptidergic neurons that play a critical role in mediat-
ing chronic22 and mechanical pain.23 Although there is still a 
controversy about the central nervous system distribution of 
TRPV1,24 several studies have demonstrated the expression 
of this channel in a wider diversity of brain regions,   including 
the hypothalamus, cerebellum, cerebral cortex, striatum, 
midbrain, olfactory bulb, medulla, hippocampus, thalamus, 
and substantia nigra.25 In non-neuronal tissues, TRPV1 
expression is detected in keratinocytes26 and melanocytes of 
the epidermis,27 bladder urothelium,28 smooth muscles,29 glial 
cells, liver, polymorphonuclear granulocytes,30 mast cells,31 
dendritic cells, and macrophages.32
TRPV1 is a nonselective cation channel with near equal 
selectivity for Na+, K+, Li+, Cs+, and Rb+ ions,1 but moderate 
selectivity for divalent cations. When activated by capsaicin, 
the permeability of Mg2+ and Ca2+ relative to Na+ (Px/PNa) 
is roughly 5 and 10, respectively.1,33,34 Lower Px/PNa values 
of 3–4 are reported when the channel is activated by heat.35 
TRPV1 is also highly permeable to protons and large polyva-
lent cations, suggesting the existence of a large pore. Several 
amino acids in the putative pore-forming region between the 
fifth and sixth transmembrane segment domains are impli-
cated in cation selectivity. Mutation of Glu-648 (E648A) 
reduces Mg2+ permeability and increases Ca2+ permeability. 
Mutation of Asp-646 (D646N) reduces Mg2+ permeability 
and blockade by the cationic dye, ruthenium red.36
The single-channel conductance of capsaicin-activated chan-
nels is approximately 90–100 pS at positive potentials. At nega-
tive potentials (−60 mV), the conductance is significantly lower, 
with values of approximately 50 pS.1 TRPV1 currents exhibit 
significant outward rectification due to a combined effect of 
voltage on both channel conductance and open probability.37
TRPV1 has different modes  
of activation
TRPV1 is a polymodal channel, activated by physical and 
chemical stimuli, including heat, vanilloids, lipids, spider 
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Figure 1 A) Putative membrane topology of a transient receptor potential vanilloid 1 subunit displaying the location of residues involved in ligand-binding, proton activation, 
and post-translational modifications. The transient receptor potential vanilloid 1 domain, and calmodulin- and phosphatidylinositol-4,5-bisphosphate-binding domains are also 
depicted. B) Side view of the ribbon structural model of two opposite monomers of the transient receptor potential vanilloid 1 channel inserted into the lipid bilayer, after 
molecular dynamic simulation. The other two monomers are not shown for clarity.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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toxins, protons, cations, and voltage.35,38,39 The channel 
is activated by noxious temperatures with a threshold of 
approximately 43°C,1 and a temperature-dependent gating 
characterized by a Q10 $ 20 (Q10 is used to estimate the 
temperature dependence of channel gating).40 The tempera-
ture threshold is highly influenced by other ligands that act 
allosterically and by the receptor phosphorylation state. 
Thus, when simultaneously activated by other ligands, the 
threshold may decrease down to 20°C. It has been proposed 
that temperature regulates TRPV1 by changing the intrinsic 
voltage sensitivity of the channel.37 The temperature sensi-
tivity of this channel is allosterically linked to chemical and 
voltage activation.20 Although the mechanisms underlying 
heat activation remain unclear, a role of the C-terminus and 
the outer pore region has been proposed.14,41
TRPV1 is activated by capsaicin, the pungent component 
of hot chili peppers. Capsaicin and related compounds, includ-
ing resiniferatoxin and olvanil, are highly lipophilic and share 
a structural similarity to several endogenous fatty acid deriva-
tives that have also been identified as TRPV1 agonists.42,43 These 
include anandamide (an endocannabinoid), N-arachidonoyl 
dopamine, oleoyldopamine, 12-hydroperoxyeicosatetraenoic 
acid  (a  lipoxygenase  product),  and  18–20  carbon 
N-acylethanolamines.44 Vanilloids interact at intracellular 
regions of TRPV1, as implied by a membrane-impermeable 
charged capsaicin analog that is only effective when applied 
cytosolically.45 Consistent with this observation, several 
intracellular molecular determinants of capsaicin binding 
have been identified. The amino acid residues, Arg-114 in 
the N-terminus and Glu-761 in the C-terminal domain, play 
a key role in ligand binding.46 In addition, Tyr-511 and Ser-
512 located between the second and third transmembrane 
segments are also critical for vanilloid binding and channel 
activation,47 and Thr-550 has also been pointed towards as 
involved in structuring the vanilloid binding site in rat and 
human TRPV1 channels.48
A pH lower than 5.0 at the extracellular side of the channel 
activates TRPV1 ion channels. Actually, ligand-, voltage-, and 
temperature-evoked gating are potentiated by mildly acidic 
extracellular pH.49 Two glutamate residues located near the 
extracellular pore-forming region appear critical for proton 
regulation, ie, Glu-648, at the loop between the fifth and sixth 
transmembrane segments, is involved in direct activation of 
the channel by strong pH (pH 4), while Glu-600 located at the 
end of the fifth transmembrane segment is important for the 
response of the channel to mildly acidic external conditions 
(pH 6.5).49 Nevertheless, neutralization of Glu-600 gives rise 
to a constitutively active channel at 37°C.49
In addition to protons, positively charged compounds 
are also able to activate TRPV1, suggesting a generalized 
activation mechanism based primarily on neutralization of 
Glu-600. External cations tend to enhance agonist-evoked 
currents, and divalent cations at high (.10 mM)34 or even 
at physiological concentrations50 gate the channel directly. 
Polyvalent cations are even more potent channel regulators. 
For instance, Gd3+ and the polyamine, spermine,51,52 sensitize 
and activate TRPV1 at micromolar concentrations. These 
actions may involve interactions at multiple acidic residues, 
ie, Glu-600, Glu-648, and Asp-646.
TRPV1 also has a voltage-dependent gating. The channel 
is activated, at least partially, at strong positive potentials 
and is deactivated at negative potentials. The sensitivity of 
voltage-dependent activation and deactivation depends on 
the recording temperature and on the presence of agonists. 
In the absence of TRPV1 activators, strong membrane 
depolarization is required to activate the channel (V0.5 of 
+150 mV at 21°C), whereas in the presence of agonists, 
much smaller depolarization suffices to gate the channel, 
namely V0.5 of 0 mV at 37°C, and +10.6 mV at 21°C in the 
presence of 50 nM capsaicin.37 Thus, the heat or ligand sen-
sitivity of TRPV1 may reflect a shift in its intrinsic voltage 
dependence. Consequently, the temperature threshold for 
TRPV1 activation is not constant, but fluctuates depending 
on the membrane potential. The voltage sensor remains 
unknown, although the fourth transmembrane segment has 
been signaled as a putative candidate to hold it. However, 
unlike voltage-gated channels, TRPV1 and other transient 
receptor potential channels lack an array of charged residues 
in their transmembrane segment domains.
From the aforementioned observations, it appears obvi-
ous that various activators of TRPV1 potentiate the effect 
evoked by others, leading to enhanced activity, suggesting a 
coupling of their receptor sites. This gating cooperativity of 
various ligands seems synergistic rather than additive20 and, 
given the polymodal and synergistic modes of activation, 
implies that the TRPV1 ion channel act as an “integrator” of 
exogenous stimuli.35 In fact, TRPV1 acts similarly in relation 
to endogenous agents, which makes it of particular relevance 
in the context of inflammation, given the wide variety of 
inflammatory agents generated in inflamed conditions.
In the continuous presence of an activating stimulus, 
TRPV1 undergoes desensitization. This phenomenon can 
occur rapidly after a prolonged single application of an 
agonist, or slowly following repeated agonist applications 
(also known as tachyphylaxia). Receptor desensitization 
is believed to occur predominantly via a Ca2+-dependent Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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  process because it is largely abolished in the absence of Ca2+. 
However, it should be noted, that some Ca2+-independent 
desensitization also occurs, especially with heat activation.53 
The Ca2+-dependent mechanism arises because of the high 
TRPV1 Ca2+ permeability, allowing Ca2+ influx to activate an 
inhibitory process. Indeed, fast desensitization was signifi-
cantly reduced in a TRPV1 mutant that possesses markedly 
reduced Ca2+ permeability.33 Furthermore, desensitization 
is attenuated by inhibitors of calcineurin, a Ca2+-activated 
phosphatase, thus linking desensitization to a dephosphory-
lation event.54 In addition, Ca2+ may signal via calmodulin, 
which interacts with TRPV1 at the N-terminal and C-terminal 
regions (positions 189–222 and 767–801). Indeed, disrup-
tion of the calmodulin C-terminal region partially inhibits 
fast desensitization.55
Regulation of TRPV1 channel 
activity
There is increasing evidence that TRPV1 is subjected to 
complex regulation manifested at several levels, from gene 
expression to post-translational modification and formation 
of receptor heteromers, as well as from subcellular com-
partmentalization and association with regulatory proteins 
to many second messengers.11
Limited information is available about what controls 
TRPV1 transcription in nociceptors. Two functional TRPV1 
promoter regions and transcription initiation sites have been 
identified in the rat, ie, a distal promoter region, P1, and a 
second more proximal promoter region, P2.56 The P1 region 
containing a classic TATA box and a downstream transcrip-
tion initiation site directs the strongest promoter activity 
within the 233-bp core fragment. The proximal promoter 
region, P2, which lacks a TATA box, contains an associated 
transcription initiation site that corresponds to the consensus 
sequence known as the “initiator” element. Alternate use of 
dual promoters may represent an important aspect of how 
TRPV1 gene expression can be dynamically regulated. Nerve 
growth factor induces activation of the GTPase Ras, which 
is coupled to the activation of both transcription and transla-
tion of TRPV1.57 Nerve growth factor positively regulates 
transcriptional activity of both rat TRPV1 promoters.
A large body of evidence indicates that post-translational 
modifications of TRPV1, such as phosphorylation mediated 
by protein kinase A, protein kinase C, and calmodulin-
dependent protein kinase, increase its activity. Phospho-
rylation at Ser-116 in the N-terminus of TRPV1 is pivotal 
in protein kinase A-mediated downregulation of TRPV1 
desensitization.58 In addition, Thr-144, Thr-370, and Ser-502 
are important in protein kinase A-mediated   phosphorylation/
sensitization of the channel. Moreover, protein kinase 
C-mediated phosphorylation of TRPV1 not only potentiates 
capsaicin-evoked or proton-evoked responses, but also 
reduces its temperature threshold, such that receptors are 
active under physiological conditions (37°C).59 Two serine 
residues on TRPV1, Ser-502 and Ser-800, have been 
recognized to be important in protein kinase C-mediated 
effects. In addition to this direct effect, protein kinase C can 
also produce phosphatidylinositol 4,5-bisphosphate (PIP2) 
hydrolysis increasing TRPV1 activity, although PIP2 has been 
proposed to be involved in sensitization of these channels by 
proinflammatory agents.59 Calmodulin-dependent protein 
kinase-mediated phosphorylation of TRPV1 at Ser-502 and 
Thr-704 plays an important role in channel activation in 
response to capsaicin application.60 In addition, calcineurin-
mediated dephosphorylation at the same sites can produce 
TRPV1 desensitization.61 Similarly, the nonreceptor cellular 
tyrosine, c-Src kinase, positively regulates TRPV1 channel 
activity by tyrosine phosphorylation.61
In addition to phosphorylation, the activity of TRPV1 may 
be regulated by N-glycosylation,62 given that extracellu-
lar Asn-604 has been identified as a glycosylation site.63 
  Similarly, adenosine 5′ triphosphate may allosterically 
modulate TRPV1 by direct interaction with the nucleotide-
binding Walker-type domains and increasing vanilloid-
induced channel activity.9 Modulation of the redox state 
also impacts the physiological activity of TRPV1, possibly 
involving the Cys-621 amino acid residue located on the 
extracellular surface.64
Another essential pathway that influences TRPV1 activity 
is the formation of signalplexes, or the physical assembly 
of signaling molecules into discrete macromolecular enti-
ties.11 Several signaling proteins have been described as 
TRPV1-interacting proteins, that could be part of a “TRPV1 
  receptome” modulating nociceptor activity. As mentioned, 
TRPV1 associates with intracellular signaling enzymes, 
including protein kinase A, protein kinase C, Src, inositol   
1,4,5-  trisphosphate, and calmodulin-dependent protein 
kinases, and also with calcineurin 2B phosphatase.65 It may 
also interact with the purinergic P2X3 receptor,66 calmodulin,67 
the membrane protein, Pirt,68 the scaffolding protein, 
AKAP79/150,69 and with cytoskeleton proteins like tubulin.70 
Protein kinases modulate channel gating by post-translational 
modification involving the phosphorylation/dephosphoryla-
tion of specific residues that, in turn, lead to a decrease in 
the temperature threshold of channel activation and a poten-
tiation of its activity, by either destabilizing the closed and Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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desensitized states and/or stabilizing the open state. Other 
proteins that bind to TRPV1 are snapin and synaptotagmin 
IX, two components of the SNARE complex that mediates 
Ca2+-dependent exocytosis.71 Although the precise role of 
snapin and synaptotagmin IX binding to TRPV1 remains 
elusive, it could be involved in sorting the receptor into 
vesicles that will be exocytosed through regulated exocytosis 
or in promoting channel recruitment to the plasma membrane 
under inflammatory conditions.
Several proteins that regulate folding (chaperones), protein 
biosynthesis, surface expression, and channel function have 
been described to associate with thermotransient receptor 
potentials. Recently, the γ-aminobutyric A receptor-  associated 
protein, a small cytosolic protein initially described by its 
ability to interact with the γ subunit of the GABAA receptor,72 
was pointed towards as a TRPV1 interacting partner with the 
cytosolic N-terminal domain of the   channel.73 Noteworthy, in 
heterologous systems, γ-aminobutyric A receptor-associated 
protein expression significantly augmented the levels of 
TRPV1 and its targeting to the plasma membrane, where it 
appears to favor the formation of receptor clusters. Function-
ally, γ-aminobutyric A receptor-associated protein appears to 
induce a decrease in channel activity.73
TRPV1 in inflammation
Inflammation is the physiological response to tissue injury 
caused by pathogens or harmful agents, and is clinically 
characterized by swelling, redness, heat, pain, and loss of 
function of the affected tissue or organ. This response is a 
complex process perfectly orchestrated by several cell types 
and chemical mediators, which initiate and regulate the nec-
essary mechanisms to remove injurious agents and repair the 
affected area. The cellular components include circulating 
monocytes, macrophages, neutrophils, lymphocytes, and den-
dritic cells, while the humoral components include cytokines 
and other chemical substances that destroy pathogens or act 
as mediators for other cells. When tissue damage occurs, 
resident immune cells, such as macrophages or dendritic 
cells, are activated and release mediators in order to initiate 
the inflammatory response. Usually, during acute inflamma-
tion, the magnitude of the inflammatory response is locally 
adjusted to the injurious condition and finally resolved, main-
taining homeostasis. However, an imbalance of the regulatory 
mechanisms is the cause of inflammation as a pathological 
process and leads to chronic inflammatory states. Regulatory 
mechanisms of inflammation include mediators of immune, 
vascular, or neural origin that maintain the inflammatory 
process within the physiological range. The role of TRPV1, 
as a major player in the process of neurogenic inflammation, 
has been traditionally considered to be neuronal. However, 
the expression of the channel in immune cells also suggests 
a contribution to the immune response.30–32,74
Inflammatory mediators are released at the site of injury 
from immune cells, such as chemokines, cytokines, pros-
taglandins, bradykinin, or growth factors, as well as from 
sensory neurons that secrete the neuropeptides, substance 
P and calcitonin gene-related peptide.75 Some of these 
mediators are able to activate directly local sensory neurons 
responsible for transducing the painful sensation that, para-
doxically, is necessary to react and to avoid or minimize 
further damage.76–80 In addition, inflammatory agents are 
responsible for nociceptor sensitization changing the per-
ception of stimuli, which leads to hyperalgesia (exaggerated 
response to a mild noxious stimulus) and/or to allodynia 
(response to a non-noxious stimulus), further minimizing 
additional damage and facilitating tissue repair. In chronic 
conditions, this process is exacerbated by synaptic changes 
at the spinal cord, a process known as central sensitization.81 
Neuronal sensitization is believed to play a pivotal role in 
the development and maintenance of chronic pathological 
pain conditions.82
Inflammatory regulation of TRPV1
Peripheral sensitization of TRPV1 by proinflammatory 
agents is mediated by different molecular mechanisms, which 
include long-term upregulation of TRPV1 expression, but 
also acute functional modification of the channel (Figure 2). 
Indeed, increased expression of the channel has been shown 
in several chronic inflammatory diseases.83–85 This process 
is also mediated by fast mobilization from a subcellular 
vesicular reservoir located near the plasma membrane that 
is recruited by SNARE-dependent exocytosis.11,86
TRPV1 sensitization by nerve growth factor has been well 
documented, and is a good example of all the inflammatory 
potentiation strategies described earlier for the modulation 
of TRPV1 function and expression. Nerve growth factor 
increases TRPV1 transcription and transport to the periph-
eral nociceptor terminal, a process mediated by the p38/
mitogen-activated protein kinase signaling pathway.87,88 Acute 
regulation of TRPV1 by nerve growth factor leads to phos-
pholipase C activation and PIP2 hydrolysis. In parallel, nerve 
growth factor activates phosphatidylinositol 3-kinase-protein 
kinase C epsilon and calmodulin-dependent protein kinase 
signaling cascades, increasing TRPV1 opening probability 
and its translocation to the cell surface from the vesicular 
pool.89–91 Similar to nerve growth factor, insulin growth Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
72
Devesa et al
factor-1 also enhances TRPV1 membrane currents through 
phosphatidylinositol 3-kinase and protein kinase C pathways, 
increasing channel activity and receptor translocation to 
the cell surface,92 inducing long-term overexpression of 
TRPV1.93 Both nerve growth factor and insulin growth 
factor-1 provoke TRPV1 plasma membrane translocation by 
SNARE-dependent neurosecretion, as was demonstrated by 
the blockade of Ca2+-dependent neuronal exocytosis with a 
botulinomimetic peptide which abolished TRPV1 potentia-
tion in dorsal root ganglion neurons.94
Cytokines, such as tumor necrosis factor alpha, 
interleukin-1β, and interleukin-6, can also regulate TRPV1 
function, increasing neuronal excitability.76,95 For instance, 
the receptors for tumor necrosis factors alpha (ie, TNFR1 and 
TNFR2) are coexpressed with TRPV1 in sensory neurons, 
where they can also produce rapid and long-term modification 
of TRPV1 function. This cytokine increases TRPV1 expres-
sion on dorsal root ganglion and trigeminal ganglion neurons 
via the extracellular signal-regulated kinase pathway.96,97 
Additionally, tumor necrosis factor alpha rapidly sensitizes 
TRPV1 activity and enhances the Ca2+ influx induced by cap-
saicin. This rapid mechanism seems to be mediated by p38/
mitogen-activated protein kinase and the c-jun N-terminal 
kinase pathway, but not by extracellular signal-regulated 
kinase.97–99 Although protein kinase C phosphorylation 
seems also to be implicated, the exact mechanism remains 
unknown.76,100–102 Tumor necrosis factor alpha can also activate 
the TRPA1 receptor, which has been implicated in maintaining 
inflammation-related pain.103 TRPA1 is coexpressed in a subset 
of TRPV1-  expressing nociceptors in trigeminal and dorsal root 
  ganglion neurons104 and functions to detect products of tissue 
injury,   inflammation, and   oxidative stress that cause pain and 
  neurogenic  inflammation.105 Under   conditions of inflammation 
or nerve injury, expression of TRPA1 is persistently increased, 
concurrent with TRPV1.106
Rapid sensitization of TRPV1 currents by interleukin-1β 
has also been shown to be mediated by protein kinase C 
activity,107 via a mechanism independent of TRPV1 surface 
translocation by SNARE-dependent exocytosis.94 Although 
little is known about the ability of interleukin-6 to sensitize 
TRPV1,78,108 exposure of dorsal root ganglion cultures to 
interleukin-6 increases TRPV1 response to heat by a mecha-
nism that involves Janus kinase and protein kinase C.109
Other inflammatory mediators, such as bradykinin, 
prostaglandin E2, adenosine 5′ triphosphate, and histamine, 
also sensitize TRPV1. Bradykinin induces excitation and 
sensitization of TRPV1 to heat via the protein kinase C 
pathway.110–112 In the same way, TRPV1 potentiation by 
adenosine 5′ triphosphate113 or by histamine114 is mediated 
via the phospholipase C/protein kinase C pathway. However, 
only adenosine 5′ triphosphate has been shown to mobilize 
TRPV1 to the plasma membrane mediated by the SNARE 
complex.94 Mechanisms involved in TRPV1 sensitization by 
prostaglandin E2 and prostaglandin I2 are through phosphory-
lation by protein kinase A,55 the receptor anchoring for which 
seems to be mediated by the protein, AKAP150,115 and also 
by protein kinase C.55
The cellular mechanisms underlying chemokine-induced 
excitation of sensory neurons include potentiation of TRPV1, 
in addition to inhibition of K+ conductance.95 CCL3 via 
the CCR1 receptor enhanced the response of dorsal root 
  ganglion neurons to capsaicin, and decreased the response to 
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hot-plate latency in mice. CCL3-mediated TRPV1 sensitiza-
tion was reduced by phospholipase C and protein kinase C 
inhibitors.116 Activation of other chemokine receptors, such 
as CCR2, also expressed in the dorsal root ganglia, produced 
sensitization of TRPV1 by phospholipase C/protein kinase 
C phosphorylation.117
TRPV1 in inflammatory conditions
Besides the direct effect of inflammatory mediators on 
TRPV1, activation of nociceptors also induces the release of 
neuropeptides which act both autocrinally on the terminals 
and paracrinally on target cells, such as mast, immune, and 
vascular smooth muscle cells.118,119 These peptides contribute 
to the destruction of the harmful agent and to the repair of 
damaged tissue. For instance, when the neuropeptides cal-
citonin gene-related peptide and substance P are released 
from sensory neurons, their vasodilatory effects facilitate the 
arrival of more immune cells and proinflammatory mediators 
at the site of injury, which contributes to plasma extravasa-
tion and swelling. In fact, direct activation of sensory nerves 
is enough to induce an inflammatory response without the 
presence of pathogens or tissue injury, a process known as 
neurogenic inflammation or sterile inflammation.120
TRPV1 is expressed in sensory neurons, mainly in pep-
tidergic neurons, found in many tissues close to blood ves-
sels, epithelia, and vascular smooth muscle.121,122 Release of 
calcitonin gene-related peptide and substance P from sensory 
neurons is induced by TRPV1 activation via a wide variety 
of physical and chemical stimuli.123 Sensitization of TRPV1 
by inflammatory mediators increases the release of these 
neuropeptides from a vesicle reservoir.97,124 Due to the proin-
flammatory effects of these neuropeptides, TRPV1 activation 
has been long considered as a proinflammatory receptor. 
  However, other neuropeptides with anti-inflammatory prop-
erties, such as somatostatin, can also be released as a conse-
quence of Ca2+ influx through the TRPV1 channel.125,126
TRPV1 acts as a transducer of noxious thermal and 
chemical stimuli in nociceptive sensory neurons, and is vital 
in mediating enhanced heat sensitivity during inflammation. 
Preclinical and clinical studies suggest that the TRPV1 recep-
tor is an important component of several disease states, such 
as pain (inflammatory, visceral, cancer, and neuropathic), 
airways disease (including chronic cough), inflammatory 
bowel disease, interstitial cystitis, urinary incontinence, 
pancreatitis, and migraine.127
Acute and chronic arthritis is characterized by debilitating 
pain, and by an increment in the levels of neuropeptides in 
synovial fluid. Due to the role of TRPV1 as an integrator of 
multiple noxious stimuli as well as its presence in neuropeptide-
containing fibers that are present in the knee joint synovium 
and adjacent bone, this channel has been implicated in 
the pathological symptoms of acute and chronic arthritis, 
although the precise mechanism is unclear.128 Keeble et al 
studied the vascular and hyperalgesic components of joint 
inflammation in wild-type and TRPV1 knockout mice after 
intra-articular injection of Freund’s complete adjuvant, and 
demonstrated that knee swelling and vascular hyperperme-
ability were significantly lowered in the joints treated with 
Freund’s complete adjuvant in TRPV1 null mice. Further-
more, intra-articular injection of tumor necrosis factor alpha 
in these mice produced decreased thermal hyperalgesia and 
joint swelling, indicating a critical role of tumor necrosis 
factor alpha and TRPV1 in the pathophysiology of rheuma-
toid arthritis.129
Cancer pain is a significant clinical problem because 
it is the first symptom of the disease in approximately 
20%–50% of all cancer patients. Bone is the most common 
site of origin of chronic pain in patients with metastatic 
lung, prostate, and breast cancers or myeloma.130 There are 
at least three mechanisms in bone cancer that may contribute 
to the activation and sensitization of TRPV1 expressed by 
sensory fibers that innervate the tumor-bearing bone.131 The 
first is acidosis produced by osteoclasts, the principal bone-
resorbing cells, and by lysis of tumor cells that have a lower 
intracellular pH than normal cells.132 The second is mediated 
by products released from cancerous tissue, like bradykinin, 
adenosine 5′ triphosphate, and nerve growth factor, which 
can modulate TRPV1 function indirectly via activation of 
second-messenger signaling pathways.130 Because the bone 
receives a rich sensory innervation by fibers that express 
TRPV1,133 production of these proalgesic agents may also 
sensitize TRPV1 channels, thereby generating a state of 
hyperalgesia and/or allodynia. Finally, the third mechanism 
is mediated directly by tumor-induced injury to primary 
afferent neurons.134 In a recent study, it has been shown that 
activation of TRPV1 was involved in bone cancer pain.135 
The investigators found increases in TRPV1 protein levels 
and in the number of TRPV1-positive neurons in the dorsal 
root ganglia from a murine model of bone cancer. In support 
of a role of TPRV1 in bone cancer pain, it has been dem-
onstrated that a receptor antagonist significantly attenuates 
painful symptoms.130
Itch, a principal symptom in skin diseases, is an impor-
tant skin manifestation of systemic diseases, and one of the 
most debilitating symptoms in allergic and atopic dermati-
tis.136 It can be triggered by localized, systemic, peripheral, Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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or central stimuli, and there are numerous pruritogenic 
substances, including neuropeptides, cytokines, proteases, 
and   histamine.137 Less is known about pathophysiologi-
cal specificity among the different diseases, but cross-talk 
between neuron terminals and dermal mast cells is being 
recognized as an important mechanism involved in patho-
genesis. TRPV1-expressing primary afferents generate 
responses to pruritogenics via multiple mechanisms, like 
PLCβ3 activation.138 In addition, keratinocytes express a wide 
range of mediators and receptors involved in itch, and TRPV1 
activation by them results in the release of pruritogenic 
mediators, as well as cellular proliferation, differentiation, 
and apoptosis.139 Histamine, the best known pruritogenic 
agent, induces itch by activating PLA2, lipoxygenase and the 
TRPV1 signaling pathway, as is shown by the decrease in 
histamine-induced scratching in TRPV1-deficient mice.140
Protective role of TRPV1 against 
inflammation
Cumulative evidence suggests that TRPV1 may have an anti-
inflammatory action in some pathological conditions. Indeed, 
the number of diseases in which TRPV1 plays a protective 
role is expanding. For instance, TRPV1 has been shown to 
have a protective role against inflammatory conditions in the 
cardiovascular system, and it has been implicated in protect-
ing against ischemia/reperfusion-induced inflammation of 
the heart.141 A similar action has been reported for liver142 
and kidney143 pathologies, thus emphasizing a new emerging 
anti-inflammatory role for TRPV1.
The TRPV1 receptor also plays a critical modulatory role 
in contact dermatitis, a chronic allergic condition typified 
by skin inflammation and itching.144 The genetic disruption 
of TRPV1 channels or blockade of the TRPV1-dependent 
sensory neurogenic component by resiniferatoxin increased 
the inflammatory response in an ear murine model of con-
tact dermatitis. This enhancement suggests that capsaicin-
sensitive neurons expressing the TRPV1 channel may act to 
downregulate the hypersensivity, possibly by influencing the 
immune state of the skin.
Another protective function of TRPV1 against inflamma-
tory conditions has been reported in the pathological condi-
tion of colitis,145 one of the disorders under the collective 
heading of gastrointestinal disturbances referred to as chronic 
inflammatory bowel diseases. Immunoreactive TRPV1 
fibers have been detected on nerve terminals within the 
myenteric ganglia and the interganglionic fibers throughout 
the gastrointestinal tract.146 Using a murine model produced 
by the infusion of 2,4-dinitrobenzene sulfonic acid through 
the rectum of mice,147 it was reported that the TRPV1 null 
mice exhibited higher levels of inflammation than wild-type 
animals, indicating a protective role of TRPV1 channels in 
the initiation of this inflammatory condition.
Although this protective action of TRPV1 may be 
surprising, given the widely known proinflammatory 
activity of this channel, it should be considered that the 
main mechanisms involved in the development of chronic 
inflammation can be drastically different in each inflam-
matory disease. For instance, TRPV1 may mediate the 
release of both proinflammatory neuropeptides (substance 
P and calcitonin gene-related peptide) in some conditions, 
and of anti-inflammatory (somatostatin) peptides in others, 
depending on which subpopulation of nociceptors is more 
abundant in the affected tissue. Likewise, the immune cells 
and inflammatory mediators involved will depend on the 
specific inflammatory process and the affected tissue. More-
over, this balance usually changes during the development of 
pathology according to the time course or state of the disease. 
Therefore, the contribution of TRPV1 should be analyzed 
in detail for each inflammatory condition along with the 
mechanism involved in the specific inflammatory process. 
This evaluation will become essential because abrogation of 
the anti-inflammatory role of TRPV1 by potent antagonists 
may lead to aggravation of the disease or to the appearance 
of side effects.
Inflammatory process of sepsis
Sepsis is defined as the systemic inflammatory response 
elicited by an infection. The clinical manifestations of sep-
sis are abnormality in at least two of the following: body 
temperature (hyperthermia or hypothermia), heart rate 
(tachycardia), respiratory rate (tachypnea), and white blood 
cell count (leukocytopenia, leukocytosis or presence of 
immature forms greater that 10%). Increasingly grave stages 
of the systemic inflammatory response to an infection are 
severe sepsis and septic shock. Sepsis is considered when 
signs of organ dysfunction are present, while septic shock 
is defined by the presence of hypotension or hypoperfusion 
which finally leads to multiple organ failure.148,149 Despite 
the advances in antibiotics and critical care, severe sepsis 
remains the leading cause of death in intensive care units, 
in part because antibiotics cannot control systemic inflam-
mation. In fact, the clinical symptoms of severe sepsis are 
not exclusively due to infection and can be also triggered by 
trauma, ischemia, severe injury, burns, or pancreatitis, which 
participate in the pathogenesis of this systemic inflammatory 
response syndrome.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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The pathogenesis of sepsis is characterized by an 
  excessive production of inflammatory mediators, mainly 
cytokines, chemokines, lipid mediators, and oxygen radi-
cals. In a normal inflammatory response, these molecules 
are necessary to enhance leukocyte infiltration at the site of 
infection, to destroy the pathogen and repair tissue damage. 
However, in sepsis, this uncontrolled production of inflam-
matory mediators ends up with excessive vasodilatation, 
capillary leakage, hypotension, tissue injury, and finally lethal 
multiple organ failure.150–152 Clinical and experimental studies 
have emphasized the role of apoptosis in sepsis. Programmed 
cell death constitutes an active process to control cell removal, 
but also plays an important role in several pathological states. 
Activation of intracellular cascades finally leads to DNA 
degradation, a process regulated by a cascade of caspases, 
which are critical molecules in programmed cell death.153,154 
Accelerated apoptosis of lymphocytes has been observed 
in animal models of sepsis and in autopsies of patients who 
died from sepsis.155
Different studies have demonstrated that the immune 
system is not the only system activated in sepsis. For instance, 
it is well known that a complex interaction exists between 
inflammation and coagulation in sepsis. The inflammatory 
response in sepsis skews the balance to a procoagulant state, 
promoting thrombus and clot formation. Indeed, patients with 
increased coagulation factors and reduced anticoagulation 
factors as a result of sepsis are prone to thrombus formation, 
compromising tissue perfusion and driving towards organ 
failure.151,156
In addition to activation of the coagulation cascades, 
extensive bidirectional communication exists between 
the immune and nervous systems in all inflammatory 
processes, which involves a huge diversity of molecular 
mechanisms.156,157 Release of inflammatory molecules can 
activate or influence sensory nerve function, which, in turn, 
can stimulate or inhibit the immune system by the release of 
neurotransmitters. In patients with sepsis, plasma levels of 
substance P and calcitonin gene-related peptide are signifi-
cantly increased, providing evidence that sensory nerves are 
activated in this pathology.158–160 These bioactive neuronal 
agents are able to induce inflammation by directly acting on 
immune cells, mast cells, vascular smooth muscle, or other 
cell types.118,119 Substance P is known to increase vascular 
permeability,161 and calcitonin gene-related peptide is a 
potent vasodilator and hypotensive agent.162 Therefore, both 
neuropeptides have been mainly considered to be involved 
in the development of inflammation. However, it has also 
been shown that calcitonin gene-related peptide can mediate 
anti-inflammatory and immunosuppressive activities. For 
instance, it modulates cell adhesion and migration, increases 
some anti-inflammatory mediators, such as interleukin-10 or 
prostaglandin I2, and inhibits proinflammatory mediators, 
such as tumor necrosis factor alpha, among others.163–168 
Consistent with these findings, administration of calcitonin 
gene-related peptide attenuated the development of some 
inflammatory and organ failure models.169,170 Neuropeptides, 
such as somatostatin, have also been recently reported to be 
increased in plasma from septic patients,171 but others, such 
as endothelin-1 or vasoactive intestinal peptide serum lev-
els, seem to remain unmodified during sepsis.172 However, 
despite these observations, progress towards understanding 
the potential involvement of sensory nerves in sepsis and 
defining the exact role of neuropeptides in the development 
of this pathology is quite limited.
Is TRPV1 involved in sepsis?
Cumulative evidence associates TRPV1 channel activity with 
a protective effect in experimental models of sepsis. The role 
of the TRPV1 channel in sepsis was first evidenced by using 
its known agonist, capsaicin, and its antagonist, capsazepine. 
Injection of capsaicin was shown to diminish mortality during 
abdominal sepsis, suggesting an important role for nocicep-
tive system in the host response to infection.173 A small dose 
of capsaicin reduced the systemic inflammatory response in 
septic rats by increasing anti-inflammatory cytokines and 
attenuating proinflammatory cytokines,174 which was con-
sistent with previous in vitro results in lipopolysaccharide-
activated peritoneal macrophages.175 In contrast, TRPV1 
blockade with capsazepine reduced channel-mediated 
protection against endotoxin-induced hypotension and 
mortality in septic rats.176 Later, similar beneficial effects 
were also shown in a different rat model of sepsis, where 
capsaicin significantly attenuated systemic inflammation 
and multiple organ damage caused by sepsis, and protected 
against mortality.177 Other TRPV1 agonists and antagonists 
have also been evaluated in different models of sepsis, all 
showing a consistent decrease in the development of sepsis 
or a reduction in some of the pathological symptoms when 
TRPV1 is activated.178–180
Recent elegant experiments performed in TRPV1 knock-
out mice lend further support to the protective role of the 
vanilloid channel in the onset of sepsis. In these animals, there 
was an enhanced development of the pathological features 
and biomarkers of the systemic inflammatory response. Early 
onset, decreased body temperature, and enhanced hypoten-
sion were shown, together with an increased level of some Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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inflammatory mediators in peritoneal exudates.181,182 At the 
same time, protective effects were also shown in another 
septic model in which TRPV1 null mice showed greater 
infiltration, more histological lesions, bronchial hyperactivity, 
and increased myeloperoxidase levels in the lungs.183
The neuropeptides involved in the protective effects of 
TRPV1 in sepsis remain to be exactly defined. Although it 
was initially suggested that TRPV1 mediated the effects of 
sepsis via substance P and the NK1 receptor,176 the regulatory 
role of the channel in sepsis was shown to be independent 
of substance P in mice lacking TRPV1.181 Alternatively, 
because calcitonin gene-related peptide, a potent vasodila-
tor, was shown to be elevated in endotoxin-treated rats,184 it 
has been considered a critical factor in the development of 
septic shock.185 Moreover, an essential role has been claimed 
for somatostatin, because somatostatin receptor blockade 
aggravates sepsis in the lungs of wild-type mice, while the 
process is attenuated by injection of this neuropeptide in 
TRPV1 knockout mice.183
It should be noted that these results have been obtained 
from different models of sepsis in rats or mice, using several 
research and pharmacological tools which could explain 
the differences observed in neuropeptides participating in 
the effects of TRPV1. Moreover, the tissue parameters and/
or biomarkers analyzed in each model are different, which 
could also contribute to the observed differences in the role 
of neuropeptides. In addition, it should not be forgotten that 
endotoxin-induced fever was shown to be initiated via the 
TRPV1 channel.186,187 However, an overall protective role 
of TRPV1 in sepsis has been proposed in most of these 
studies, and the increased levels of some neuropeptides in 
septic patients could be due to compensatory mechanisms 
of the organism when trying to control the systemic inflam-
matory process.
Although understanding of the pathogenesis of inflamma-
tion and sepsis has improved, this has not translated into clini-
cal benefit. Therapies for severe sepsis are mainly focused 
on eradication of infection and on maintenance of systemic 
perfusion. Despite advances in adjuvant treatments, mortality 
remains high. In past decades, therapeutic attempts have been 
focused on inflammatory mediators and processes, but they 
have failed to translate into efficacy in clinical trials, although 
animal models have shown promising and successful results. 
The benefit of corticosteroid therapy in severe sepsis and 
septic shock remains controversial. Activated protein C, one 
of the coagulation factors, is the only treatment for sepsis 
approved by the Food and Drug Administration, which is 
projected to be useful only in a small subset of patients with 
severe sepsis. The proposed protective role of TRPV1 implies 
that antiseptic treatments should preserve its channel activity. 
Thus, until the role of TRPV1 in sepsis is well understood, 
potent channel antagonists should be used with caution to 
treat the septic inflammatory process.
Conclusion
It is becoming clear that TRPV1 contributes to the pathophys-
iology of inflammatory processes. Intriguingly, this channel 
may have both a proinflammatory and anti-inflammatory 
action, depending on the disease. Thus, although it was 
widely accepted that TRPV1 blockers will become a new 
generation of anti-inflammatory and analgesic drugs to 
treat a plethora of human diseases, their clinical use must 
be reconsidered, because of the newly identified protective 
roles assigned to TRPV1. We are learning that some of the 
protective anti-inflammatory effects of TRPV1 were most 
probably ignored or misinterpreted. Therefore, the better 
we understand how TRPV1 works and how it contributes 
to human physiology and pathology, the more challeng-
ing it will be to find compounds that target pathological 
proinflammatory TRPV1 channels, without altering physi-
ologically working and anti-inflammatory subpopulations of 
channels. Perhaps targeting inflammatory expression and/or 
recruitment of channels may provide a superior therapeutic 
paradigm to attenuate inflammation.
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